InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 217.46% from the company’s current price.

InflaRx Stock Performance

IFRX opened at $2.52 on Thursday. The business’s 50-day simple moving average is $2.26 and its 200 day simple moving average is $1.78. InflaRx has a 52-week low of $1.16 and a 52-week high of $2.82. The firm has a market capitalization of $148.38 million, a PE ratio of -2.33 and a beta of 1.66.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.